Multiple Myeloma Drugs Market by Therapy, Distribution channel, and Geography - Forecast and Analysis 2023-2027

Published: Oct 2022 Pages: 167 SKU: IRTNTR74700

Multiple Myeloma Drugs Market Forecast Analysis 2023:2027

The multiple myeloma drugs market size is estimated to grow at a CAGR of 5.9% between 2022 and 2027. The multiple myeloma drugs market size is forecast to increase by USD 6,419.94 million. The growth of the market depends on several factors, including the increase in the incidence of multiple myeloma, Proteasome inhibition has arisen, and an increase in the multiple myeloma drugs contributes to the growth of the market. 

This market report extensively covers market segmentation by therapy (targeted therapy, biologic therapy, chemotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-pharmacy), and geography (North America, Europe, Asia, and Rest o the World (row). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

 What will the Size of the Multiple Myeloma Drugs Market be During the Forecast Period?

To learn more about this report, View Report Sample

 

Multiple Myeloma Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The growing incidence of multiple myeloma is notably driving the drug market growth, although factors such as the increase the popularity of complementary and alternative medicine may hamper the market growth.  Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Multiple Myeloma Drugs Market Driver 

The growing incidence of multiple myeloma is a key factor driving the drugs market growth. One of the major drivers of the drugs market is the increasing incidence of multiple myeloma globally. Multiple myeloma is the most common type of myeloma, with more than 90% of patients diagnosed with myeloma having multiple myeloma. Multiple myeloma is the prime target indication for the vendors in the market, as there is a huge opportunity for them. Despite the recent advances in the treatment landscape for multiple myeloma, including the approval of three proteasome inhibitors, the market has witnessed an increase in the number of new cases of myeloma.

The incidence rate of the indication has been increasing at a significant rate owing to rising risk factors such as the increase in the geriatric population and obesity and plasma cell anomalies, including monoclonal gammopathy of undetermined significance and solitary plasmacytoma. As a result, the market is expected to benefit significantly from the increasing incidence of multiple myeloma during the forecast period.

Key Multiple Myeloma Drugs Market Trends

The emergence of nanomedicine platforms will fuel the emergence of nanomedicine, which is likely to have a positive impact on the market. Lipid-based nanoparticles and polymer-based approaches for drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, the nanotechnology approach could radically lower this need, allowing much earlier diagnosis and treatment regimes. Nanocarriers facilitate the delivery of drugs specifically to cancer cells by directing cellular events at the nanometer scale.

One of the major clinical advantages of the nanocarrier-based approach over conventional drugs is the specific delivery of many chemotherapeutic agents per recognition event. Particulate nanocarriers and polymer conjugates increase the drug portfolio available to oncologists. The market is also witnessing new research studies evaluating the use of nanoparticles for more effective drug delivery. Therefore, the emergence of nanomedicine platforms will further drive the growth of the market during the forecast period.

Key Multiple Myeloma Drugs Market Challenge

The growing popularity of complementary and alternative medicine is a major challenge to the drugs along with the increasing side effects of conventional drugs, individuals are seeking CAM (Complementary and alternative medicine) therapies. The increased demand for these therapies is also due to the high cost of multiple myeloma therapeutics. Some of the CAM therapies include mind and body medicines, biology-based practices, energy work, and whole medical systems. These solutions include meditation, biofeedback, yoga, massage, ayurvedic medicine, and naturopathic medicine.

The growing demand for these therapies has driven healthcare organizations to undertake research that facilitates the use of CAM therapies for the treatment of multiple myeloma. For instance, the National Cancer Research Institute has established the Palliative and Supportive Care Clinical Studies Development Group to carry out several studies in the UK. Such initiatives are expected to hamper market growth during the forecast period.

Key Multiple Myeloma Drugs Market Customer Landscape

The multiple myeloma drugs market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Multiple Myeloma Drugs Market Customer Landscape

Who are the Major Multiple Myeloma Drugs Market Vendors?                                     

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

  • amgen.com - The company offers multiple myeloma drugs such as Kyprolis. Also, this segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Parent Market Analysis

Technavio categorizes the multiple myeloma drugs market as a part of the  Pharmaceuticals & within the global Healthcare Industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

What is the Fastest-Growing Segments in the Multiple Myeloma Drugs Market?

The market share growth by the targeted therapy segment will be significant during the forecast period. Targeted therapy focuses on specific abnormalities within cancer cells that enable them to survive. Targeted therapies are mainly classified into proteasome inhibitors and histone deacetylase inhibitors. Some of the proteasome inhibitors include VELCADE (bortezomib) and KYPROLIS (carfilzomib). Histone deacetylase inhibitors include FARYDAK (panobinostat). 

Get a glance at the market contribution of various segments  Request a PDF Sample

The targeted therapy segment showed a gradual increase in market share from USD 8,546.73 million in 2017 and continued to grow by 2021. FARYDAK (panobinostat) drugs block the action of a substance in myeloma cells that disrupt proteins. This action helps in killing the myeloma cells. VELCADE was approved for the treatment of multiple myeloma in people who had already been treated with chemotherapy. Later, in 2008, the drug was approved for use in the initial phase of treatment also. VELCADE has started witnessing sales erosion over the last couple of years due to the expiry of its patent, with the annual sales of the drug declining by nearly 6% in 2021.

However, more recent drug approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. For instance, KYPROLIS from Amgen registered an annual sales growth of 7% in 2021.

Which are the Key Regions for the Multiple Myeloma Drugs Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 36% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America is expected to benefit significantly from the heavy sales of approved myeloma drugs in the region for its treatment. Currently, three branded multiple myeloma drugs and one generic proteasome inhibitor are approved in the region.

The expiry of the patent on the blockbuster drug, VELCADE, has resulted in the development of generic versions of the drug by various large- and mid-sized pharmaceutical companies in the region. Currently, five vendors in the market are developing a generic version of VELCADE, with large vendors such as Fresenius already operating in the market, while Allergan's generic version is being registered for the treatment of multiple myeloma. This is expected to increase the demand for drugs in the region during the forecast period.

Segment Overview

The multiple myeloma drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by type, product, distribution channel, and region.

  • Therapy Outlook ( USD Million, 2017 - 2027)
    • Targeted therapy
    • Biologic therapy
    • Chemotherapy
    • Others
  • Distribution channel Outlook ( USD Million, 2017 - 2027)
    • Hospital pharmacy
    • Retail pharmacy
    • E-pharmacy
  • Region Outlook ( USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • APAC
      • China
      • India
    • ROW
      • Brazil
      • Australia
      • Argentina
      • Rest of the World

Multiple Myeloma Drugs Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.9%

Market growth 2023-2027

$ 6419.94 million

Market structure

Fragmented

YoY growth (%)

5.76

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Multiple Myeloma Drugs Market Report?

  • CAGR of the market during the forecast period.
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the size of the multiple myeloma drugs market size and its contribution of the market in focus to the parent market.
  • Accurate predictions about upcoming trends and changes in consumer behavior.
  • Growth of the multiple myeloma drugs market industry across North America, Europe, Asia, and Rest of World (ROW).
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors.
  • Comprehensive analysis details of factors that will challenge the growth of multiple myeloma drugs market vendors.

 

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global multiple myeloma drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global multiple myeloma drugs market 2017 - 2021 ($ million)
    • 4.2 Therapy Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)
    • 4.3 Distribution Channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Therapy

    • 6.1 Market segments
      • Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
    • 6.2 Comparison by Therapy
      • Exhibit 32: Chart on Comparison by Therapy
      • Exhibit 33: Data Table on Comparison by Therapy
    • 6.3 Targeted therapy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
    • 6.4 Biologic therapy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Biologic therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Biologic therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Biologic therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Biologic therapy - Year-over-year growth 2022-2027 (%)
    • 6.5 Chemotherapy - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
    • 6.6 Others - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.7 Market opportunity by Therapy
      • Exhibit 50: Market opportunity by Therapy ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 51: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 52: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 53: Chart on Comparison by Distribution Channel
      • Exhibit 54: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacy - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
    • 7.4 Retail pharmacy - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • 7.5 E-pharmacy - Market size and forecast 2022-2027
      • Exhibit 63: Chart on E-pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on E-pharmacy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on E-pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on E-pharmacy - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 67: Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 69: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 70: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 71: Chart on Geographic comparison
      • Exhibit 72: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 109: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 110: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 112: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 113: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 114: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 115: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 116: Abbott Laboratories - Overview
              • Exhibit 117: Abbott Laboratories - Business segments
              • Exhibit 118: Abbott Laboratories - Key news
              • Exhibit 119: Abbott Laboratories - Key offerings
              • Exhibit 120: Abbott Laboratories - Segment focus
            • 12.4 AbbVie Inc.
              • Exhibit 121: AbbVie Inc. - Overview
              • Exhibit 122: AbbVie Inc. - Product / Service
              • Exhibit 123: AbbVie Inc. - Key offerings
            • 12.5 Amgen Inc.
              • Exhibit 124: Amgen Inc. - Overview
              • Exhibit 125: Amgen Inc. - Product / Service
              • Exhibit 126: Amgen Inc. - Key offerings
            • 12.6 Bristol Myers Squibb Co.
              • Exhibit 127: Bristol Myers Squibb Co. - Overview
              • Exhibit 128: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 129: Bristol Myers Squibb Co. - Key offerings
            • 12.7 Daiichi Sankyo Co. Ltd.
              • Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 131: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 134: Daiichi Sankyo Co. Ltd. - Segment focus
            • 12.8 F. Hoffmann La Roche Ltd.
              • Exhibit 135: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 136: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 140: GlaxoSmithKline Plc - Overview
              • Exhibit 141: GlaxoSmithKline Plc - Business segments
              • Exhibit 142: GlaxoSmithKline Plc - Key offerings
              • Exhibit 143: GlaxoSmithKline Plc - Segment focus
            • 12.10 Johnson and Johnson
              • Exhibit 144: Johnson and Johnson - Overview
              • Exhibit 145: Johnson and Johnson - Business segments
              • Exhibit 146: Johnson and Johnson - Key news
              • Exhibit 147: Johnson and Johnson - Key offerings
              • Exhibit 148: Johnson and Johnson - Segment focus
            • 12.11 Merck and Co. Inc.
              • Exhibit 149: Merck and Co. Inc. - Overview
              • Exhibit 150: Merck and Co. Inc. - Business segments
              • Exhibit 151: Merck and Co. Inc. - Key news
              • Exhibit 152: Merck and Co. Inc. - Key offerings
              • Exhibit 153: Merck and Co. Inc. - Segment focus
            • 12.12 Novartis AG
              • Exhibit 154: Novartis AG - Overview
              • Exhibit 155: Novartis AG - Business segments
              • Exhibit 156: Novartis AG - Key offerings
              • Exhibit 157: Novartis AG - Segment focus
            • 12.13 Pfizer Inc.
              • Exhibit 158: Pfizer Inc. - Overview
              • Exhibit 159: Pfizer Inc. - Product / Service
              • Exhibit 160: Pfizer Inc. - Key news
              • Exhibit 161: Pfizer Inc. - Key offerings
            • 12.14 PharmaMar SA
              • Exhibit 162: PharmaMar SA - Overview
              • Exhibit 163: PharmaMar SA - Business segments
              • Exhibit 164: PharmaMar SA - Key news
              • Exhibit 165: PharmaMar SA - Key offerings
              • Exhibit 166: PharmaMar SA - Segment focus
            • 12.15 Sanofi SA
              • Exhibit 167: Sanofi SA - Overview
              • Exhibit 168: Sanofi SA - Business segments
              • Exhibit 169: Sanofi SA - Key news
              • Exhibit 170: Sanofi SA - Key offerings
              • Exhibit 171: Sanofi SA - Segment focus
            • 12.16 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.17 Teva Pharmaceutical Industries Ltd.
              • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 177: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 178: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 179: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 180: Teva Pharmaceutical Industries Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 181: Inclusions checklist
                • Exhibit 182: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 183: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 184: Research methodology
                • Exhibit 185: Validation techniques employed for market sizing
                • Exhibit 186: Information sources
              • 13.5 List of abbreviations
                • Exhibit 187: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              multiple myeloma drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis